WHO ICTRP trial
Evaluate Efficacy and Safety of Saxagliptin in Adult Indian Patients with Type 2…
CTRI/2009/091/000217 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2009/091/000217 |
|---|---|
| Public title | Evaluate Efficacy and Safety of Saxagliptin in Adult Indian Patients with Type 2 Diabetes inadequate glycemic control. |
| Scientific title | A 24-Week National, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase IIIb study in India to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control with Diet and Exercise. |
| Primary sponsor | AstraZeneca AB |
| Secondary sponsors | Collaborator BristolMyers Squibb |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: null- Type 2 Diabetes Health Condition 2: E119- Type 2 diabetes mellitus without complications |
| Interventions | Intervention1: saxagliptin: Plain, yellow, biconvex, round,film coated. Treatment is planned for 24 weeks Control Intervention1: Placebo: Plain,yellow,biconvex,round,film coated tablet to match saxagliptin |
| Registration date | May 29, 2009 |
| Target size | 213 |
| Secondary IDs | D1680C00008 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: